BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 3537219)

  • 1. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
    Cheson BD; Jasperse DM; Simon R; Friedman MA
    J Clin Oncol; 1986 Dec; 4(12):1857-64. PubMed ID: 3537219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nursing care of the patient receiving subcutaneous low-dose Ara-C therapy.
    Sticklin LA; Dubbelde K; Larson E
    Oncol Nurs Forum; 1989; 16(3):365-9. PubMed ID: 2734216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review.
    Bolwell BJ; Cassileth PA; Gale RP
    Leukemia; 1987 Aug; 1(8):575-9. PubMed ID: 3312846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes.
    Aul C; Schneider W
    Cancer; 1989 Nov; 64(9):1812-8. PubMed ID: 2790694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine.
    Larson RA; Wernli M; Le Beau MM; Daly KM; Pape LH; Rowley JD; Vardiman JW
    Blood; 1988 Oct; 72(4):1333-9. PubMed ID: 3167210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The clinical effect of low-dose Ara-C in patients with refractory acute nonlymphocytic leukemia and myelodysplastic syndrome].
    Yoshida M; Tsunoda S; Akutsu M; Furukawa Y; Takeda K; Akashi M; Komatsu N; Muroi K; Ikeda K; Ohsaka A
    Gan To Kagaku Ryoho; 1987 Apr; 14(4):1057-62. PubMed ID: 3566302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effects of low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes].
    Kanamori H; Maruta A; Fukawa H; Harano H; Kodama F; Miyashita H; Matsuzaki M; Noguchi T; Murata T; Hashimoto Y
    Rinsho Ketsueki; 1991 Feb; 32(2):108-14. PubMed ID: 2027236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
    Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
    Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemia cutis. Analysis of 50 biopsy-proven cases with an emphasis on occurrence in myelodysplastic syndromes.
    Longacre TA; Smoller BR
    Am J Clin Pathol; 1993 Sep; 100(3):276-84. PubMed ID: 8379536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
    Hasle H; Kerndrup G; Yssing M; Clausen N; Ostergaard E; Jacobsen N; Jacobsen BB
    Leukemia; 1996 Aug; 10(8):1269-73. PubMed ID: 8709630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis.
    Okamoto T; Kanamaru A; Shimazaki C; Motoji T; Takemoto Y; Takahashi M; Fukushima T; Takeshita A; Kusumoto GS; Kishimoto Y; Yorimitsu S; Tsukuda K; Uike N; Arima N; Ohno R
    Int J Hematol; 2000 Aug; 72(2):200-5. PubMed ID: 11039669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Beran M; Kantarjian H
    Semin Hematol; 1999 Oct; 36(4 Suppl 8):3-10. PubMed ID: 10622223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide, cytosine arabinoside and methotrexate versus cytosine arabinoside and thioguanine for acute non-lymphocytic leukemia in adults.
    Skeel RT; Costello W; Bennett JM; Oken MM; Tobin MS; Bertino JR; Marsh JC; Carbone PP
    Cancer; 1980 Jan; 45(2):224-31. PubMed ID: 6985830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
    Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of small doses cytosine arabinoside (Ara-C) on leukemic cells in vitro and in vivo. Results in patients with leukemia and myelodysplastic syndrome.
    Kuliczkowski K; Kotlerek-Haus S; Frydecka I; Sedek K; Nowicka J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):738-48. PubMed ID: 2436986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
    Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
    Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.